Genelux (GNLX) Cash from Operations (2022 - 2026)
Genelux (GNLX) posted quarterly Cash from Operations of 6059000.0 for Q1 2026, down 11.48% year-over-year from 6844869.05 in Q1 2025, and up 2.26% quarter-over-quarter from 6199000.0 in Q4 2025.
Genelux (GNLX) Cash from Operations (2022 - 2026) Analysis & Trends
Genelux's Cash from Operations history runs 5 years deep, the most recent figure standing at 6059000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 11.48% year-over-year to 6059000.0; the TTM figure through Mar 2026 stood at 25892000.0 (down 16.06% YoY), while the FY2025 annual figure was 25268000.0, down 19.03% from the prior year.
- Cash from Operations for Q1 2026 stood at 6059000.0, up from 6199000.0 in the prior quarter.
- The five-year high for Cash from Operations was 2825000.0 in Q1 2022, with the low at 7065000.0 in Q2 2025.
- The 5-year median for Cash from Operations is 5435000.0 (2025), against an average of 4768200.0.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 355.2% in 2023, then jumped 37.74% in 2024.
- Genelux's Cash from Operations stood at 1518000.0 in 2022, then sank by 355.2% to 6910000.0 in 2023, then surged by 37.74% to 4302000.0 in 2024, then tumbled by 44.1% to 6199000.0 in 2025, then advanced by 2.26% to 6059000.0 in 2026.
- Business Quant data shows GNLX's Cash from Operations at 6059000.0 in Q1 2026, 6199000.0 in Q4 2025, and 6569000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | -6.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.06 Mn |
| Mar 31, 2026 | -6.06 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Sep 30, 2025 | -6.57 Mn |
| Sep 30, 2025 | -6.57 Mn |
| Jun 30, 2025 | -7.07 Mn |
| Jun 30, 2025 | -7.07 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Dec 31, 2024 | -4.30 Mn |
| Dec 31, 2024 | -4.30 Mn |
| Sep 30, 2024 | -5.75 Mn |
| Sep 30, 2024 | -5.75 Mn |
| Jun 30, 2024 | -6.82 Mn |
| Jun 30, 2024 | -6.82 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Dec 31, 2023 | -6.91 Mn |
| Dec 31, 2023 | -6.91 Mn |